Peptide binding identifies an ERα conformation that generates selective activity in multiple in vitro assays

被引:4
作者
Larson, CJ
Osburn, DL
Schmitz, K
Giampa, L
Mong, SM
Marschke, K
Seidel, HM
Rosen, J
Negro-Vilar, A
机构
[1] Ligand Pharmaceut Inc, Dept Mol & Cell Biol, San Diego, CA 92121 USA
[2] Ligand Pharmaceut Inc, Dept New Leads Discovery Ligand Pharmaceut, San Diego, CA 92121 USA
关键词
agonism; Ga14 DNA-binding domain; ligand-binding domain; nuclear receptor; selective estrogen receptor modulator;
D O I
10.1177/1087057105275983
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Drugs such as tamoxifen, which act at the estrogen receptor (ER), have very different in vitro and in vivo effects from those of the native hormone. Previous research has established that different ligands induce distinct conformational changes in the ER, thus affecting the interactions of the receptor with cell-specific coactivating or corepressing proteins (cofactors) and estrogen response elements (EREs), thus potentially driving differing biological effects. Affinity-selected peptides have been used to probe the conformational changes that occur within the ER upon binding various ligands. In this study, the authors characterize the ability of several peptides to be recruited to liganded ER under cellular conditions. Approximating ER conformation via recruitment of this peptide to the ER is concluded to be a better predictor of the agonist nature of an ER ligand under these different cellular contexts than is a canonical cotransfection transactivation assay.
引用
收藏
页码:590 / 598
页数:9
相关论文
共 40 条
[1]   LACK OF ESTROGENIC POTENTIAL OF PROGESTERONE OR 19-NOR-PROGESTERONE-DERIVED PROGESTINS AS OPPOSED TO TESTOSTERONE OR 19-NOR-TESTOSTERONE DERIVATIVES ON ENDOMETRIAL ISHIKAWA CELLS [J].
BOTELLA, J ;
DURANTI, E ;
VIADER, V ;
DUC, I ;
DELANSORNE, R ;
PARIS, J .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 55 (01) :77-84
[2]  
CHAN L, 1978, VITAM HORM, V36, P259
[3]  
Chang CY, 1999, MOL CELL BIOL, V19, P8226
[4]   Selective estrogen receptor modulators: Clinical spectrum [J].
Cosman, F ;
Lindsay, R .
ENDOCRINE REVIEWS, 1999, 20 (03) :418-434
[5]   MENOPAUSAL ESTROGEN REPLACEMENT THERAPY AND BREAST-CANCER [J].
DUPONT, WD ;
PAGE, DL .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :67-72
[6]   THE EFFECT OF POSTMENOPAUSAL ESTROGEN THERAPY ON BONE-DENSITY IN ELDERLY WOMEN [J].
FELSON, DT ;
ZHANG, YQ ;
HANNAN, MT ;
KIEL, DP ;
WILSON, PWF ;
ANDERSON, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (16) :1141-1146
[7]   A LIGAND-INDUCED CONFORMATIONAL CHANGE IN THE ESTROGEN-RECEPTOR IS LOCALIZED IN THE STEROID BINDING DOMAIN [J].
FRITSCH, M ;
LEARY, CM ;
FURLOW, JD ;
AHRENS, H ;
SCHUH, TJ ;
MUELLER, GC ;
GORSKI, J .
BIOCHEMISTRY, 1992, 31 (23) :5303-5311
[8]   HORMONE-THERAPY TO PREVENT DISEASE AND PROLONG LIFE IN POSTMENOPAUSAL WOMEN [J].
GRADY, D ;
RUBIN, SM ;
PETITTI, DB ;
FOX, CS ;
BLACK, D ;
ETTINGER, B ;
ERNSTER, VL ;
CUMMINGS, SR .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (12) :1016-1037
[9]   Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements [J].
Hall, JM ;
McDonnell, DP ;
Korach, KS .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (03) :469-486
[10]   Development of peptide antagonists that target estrogen receptor β-coactivator interactions [J].
Hall, JM ;
Chang, CY ;
McDonnell, DP .
MOLECULAR ENDOCRINOLOGY, 2000, 14 (12) :2010-2023